TY -的T1 -急性Anti-Migraine处方变化根据基线心血管风险和临床特征:一个真实的证据神经学研究(p4.10 - 017) JF -乔-神经学六世- 92 - 15补充SP - p4.10 - 017 AU -胡李盟-莫里斯·文森特盟张翔AU -罗伯特Goodloe盟椎名极光Y1 - 2019/04/09 UR - http:/首页/www.ez-admanager.com/content/92/15_supplement/p4.10 - 017. -文摘N2 -目的:描述基线人口统计学和临床特点在偏头痛患者中使用心血管疾病风险评分(DRS)和测试假设偏头痛患者减少心血管疾病的风险因素更容易收到曲普坦处方在实际设置。背景:药物能引起血管收缩,并可能增加严重缺血性事件的风险。批准曲普坦标签表明药物在缺血性心血管疾病患者禁忌。因此,triptan-exposed根据实际设置的标准治疗偏头痛患者可能有较低的基线相比triptan-unexposed偏头痛患者心血管疾病的风险。设计/方法:回顾性队列研究特征之间的基线特征三个病人急性anti-migraine军团(曲普坦、鸦片、处方非甾体类抗炎药),治疗偏头痛,和一般的病人队列与年龄、性别、索引日期和保险类型。逻辑回归模型的开发和验证治疗偏头痛患者中,这一预测心肌梗死(MI)的风险在这些病人。随后,DRS生成使用预测模型进行验证。使用美国进行了分析的索赔保险数据库。结果:455776曲普坦研究发现,52793年的鸦片,和325419年处方为migraine-treated患者非甾体抗炎药,治疗偏头痛患者中,1240116和4960339匹配一般病人。Triptan-prescribed偏头痛患者年轻(37.62±12.31岁),减少心血管疾病的风险因素(如高血压、糖尿病和高脂血症),基线住院,伴随药物使用与其他研究相比军团。此外,DRS的分布表明,更大比例的鸦片的病人(2.7%)和非甾体抗炎药(3.4%)相比,曲普坦患者(0.9%)在最高1年MI的风险类别(在10%)。结论:偏头痛患者更多的心血管风险因素和更高的1年期MI风险被鸦片和非甾体抗炎药与药物相比不成比例的规定。 Future research should explore the unmet needs for migraine patients with conditions for which triptan therapy is contraindicated.Disclosure: Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Li holds stock and/or stock options in Eli Lilly and Company. Dr. Vincent has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Vincent holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Vincent was involved as an investigator. Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Zhang holds stock and/or stock options in Eli Lilly and Company. Dr. Goodloe has nothing to disclose. Dr. Aurora has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. ER -